In conversation with Mathias Alder, CEO of Gain Therapeutics discussing his personal life insights and professional achievements in the field of Computational Drug Discovery. Matt Pillar: A few months ago, I set out to learn as much about computational biology and as myriad applications in Biotech as I could. And on more than one occasion, that effort led me to a Zoom call with Matthias Alder. That my inquiry resulted in multiple opportunities to talk with Matthias made me happy. One, because he’s a really great guy, and two, because while his company’s drug discovery model leans heavily into proprietary structure based computational methods, he’s not one of these bombastic, over the top futurists who’s all in on relinquishing science to the algorithms. Just the opposite, he’s pragmatic and practical about the advantages and the limitations of deploying computational tools in an industry whose mission it is to save lives by injecting things into living human bodies.